Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561869 | 1.00 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL904452 | 0.83 | LGMN (0.73) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL1850980 | 0.83 | GAA (0.56) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL30561859 | 0.81 | MAPT (0.65) | LGMNMAPTALOX15NPC1RAB9A | |
| SCHEMBL22716931 | 0.80 | LGMN (1.00) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL520439 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL31473820 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL78755 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL8060791 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 | |
| SCHEMBL17742335 | 0.79 | LGMN (0.67) | LGMNMAPTSMN1; SMN2ALOX15NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116836130-B | Synthesis method of 3, 4-dihydrobenzothiadiazine compound | 嘉实（湖南）医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116870016-A | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116836130-A | Synthesis method of 3, 4-dihydrobenzothiadiazine compound | 嘉实（湖南）医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-115785154-A | Heteroaromatic ring compounds and medical use thereof | 希格生科（深圳）有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022253081-A1 | PHOSPHINE OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 希格生科（深圳）有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2021073498-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | 贝达药业股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | LGMN 4693/4885MAPT 955/4885SMN1; SMN2 1521/4885 |
| US-20230133169-A1 | EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF | EGFR, ERBB2, ERBB3 | LGMN 1356/4885MAPT 2358/4885SMN1; SMN2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.